Brind.

Spyre Therapeutics Prices Public Offering of Shares

1 report, 1 independent Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Spyre Therapeutics, Inc. announced the pricing of its public offering of 4,117,648 shares of common stock at $85.00 per share. The gross proceeds from the offering are expected to be approximately $350.0 million. The offering is scheduled to close on or about October 7, 2026, and includes an option for underwriters to purchase up to an additional $52.5 million in shares.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The capital raised by Spyre Therapeutics, Inc. is intended to advance its programs in Gastroenterology, Rheumatology, and Dermatology. The offering was managed by joint book-running managers, including Leerink Partners and Stifel, which generates underwriting revenue for the financial institutions involved.

From manilatimes.net

Who's involved

  • Leerink partnersJoint book-running manager for the public offering
  • StifelJoint book-running manager for the public offering
  • companyIssuer of the common stock in the public offering

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Leerink partnersSpeculative

    Leerink Partners could see increased revenue from underwriting commissions related to the equity offering.

  • StifelSpeculative

    Stifel could see increased revenue from underwriting commissions related to the equity offering.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped